VarmX has been awarded a follow-on equity investment of €15 million from the European Innovation Council (EIC) Accelerator.   The company is working to develop innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.  The funds received from the investment will be used for the further […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!